Home › Cancro pancreatico › North Carolina › Durham
Studi clinici su Cancro pancreatico a Durham, NC
24 studi su Cancro pancreatico cercano partecipanti presso sedi a Durham e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
The Vanguard Study: Testing a New Way to Screen for Cancer
In reclutamentoVolontari sani benvenuti
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi di distanza
A Study of PHN-012 in Patients With Advanced Solid Tumors
In reclutamentoFase 1
- PHN-012-001 Site, Durham
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
In reclutamentoFase 3
- Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
In reclutamentoStudio osservazionale
- Research Site, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
In reclutamentoFase 2/3
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi di distanza
- University of North Carolina Hospitals at Hillsborough, Hillsborough · a 13 mi di distanza
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
In reclutamentoFase 3
- Duke Cancer Center, Durham
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
In reclutamentoFase 3
- Investigative Site US035, Chapel Hill · a 10 mi di distanza
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
In reclutamentoFase 1/2
- Duke University Medical Center, Durham
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
In reclutamentoFase 2
- Local Institution - 0100, Durham
Promoting CT Engagement for Pancreatic Cancer With App
In reclutamento
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi di distanza
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
In reclutamentoStudio osservazionale
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi di distanza
- University of North Carolina-Hillsborough Campus, Hillsborough · a 13 mi di distanza
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
In reclutamentoFase 2
- University of North Carolina, Chapel Hill · a 10 mi di distanza
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
In reclutamentoFase 1
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · a 10 mi di distanza
- University of North Carolina, Chapel Hill · a 10 mi di distanza
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
In reclutamentoFase 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi di distanza
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
In reclutamentoFase 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi di distanza
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
In reclutamentoFase 2
- Duke University Medical Center, Durham
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
In reclutamentoFase 1
- Duke Cancer Institute /ID# 276267, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
In reclutamentoFase 1
- Research Site, Durham
Autologous CAR-T Cells Targeting B7-H3 in PDAC
In reclutamentoFase 1
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi di distanza
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
In reclutamentoFase 1
- Duke Cancer Center, Durham
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
In reclutamentoFase 1/2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi di distanza
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
In reclutamentoFase 2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi di distanza
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Chapel Hill · a 10 mi di distanza
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
In reclutamentoFase 2
- University of North Carolina, Chapel Hill · a 10 mi di distanza
Studi su Cancro pancreatico in altre città
- Houston, TX61 studi
- New York City, NY60 studi
- Boston, MA43 studi
- Nashville, TN39 studi
- Los Angeles, CA35 studi
- St. Louis, MO33 studi
- Arlington, VA33 studi
- Baltimore, MD31 studi
- San Antonio, TX31 studi
- Philadelphia, PA26 studi
- Tampa, FL26 studi
- San Diego, CA24 studi
Altri studi a Durham
- Cancro al seno64 studi
- Cancro (tutti i tipi)58 studi
- Cancro del polmone non a piccole cellule39 studi
- Mieloma multiplo37 studi
- Leucemia mieloide acuta33 studi
- Cancro metastatico33 studi
- Cancro alla prostata32 studi
- Cancro ai polmoni32 studi
- Cancro colorettale28 studi
- Cancro ovarico27 studi
- Leucemia linfatica cronica27 studi
- Insufficienza cardiaca26 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.